<DOC>
	<DOCNO>NCT02452736</DOCNO>
	<brief_summary>The purpose study conduct prospective , multi-center , single arm , non-randomized evaluation acute outcomes Chinese subject , include eligible percutaneous transluminal coronary angioplasty ( PTCA ) reference vessel diameter 2.25 mm 4.0 mm , Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System .</brief_summary>
	<brief_title>Acute Safety , Deliverability Efficacy Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System Treatment Suitable Patients According Indication Use ( CHINA RESOLUTE INTEGRITY STUDY )</brief_title>
	<detailed_description>This Pre-market , Prospective , Multi-center , Single arm , Non-randomized Study . The objective study : - To assess deliverability Resolute Integrity Stent suitable patient accord Indication Use reference vessel diameter ( RVD ) 2.25 mm 4.0 mm 200 evaluable patient - To assess in-hospital Major Adverse Cardiac Event ( MACE ) rate - To collect data resource utilization catheterization lab . At least 200 evaluable patient 15 study center China meet eligibility criterion sign inform consent form participate study . The expected time participation study subject inform consent sign-off hospital discharge . An angiographic core laboratory Clinical Events Committee ( CEC ) utilize . Adjudication pre-specified clinical endpoint event do independent Clinical Events Committee . An angiographic core laboratory review baseline , procedural , clinical event angiogram patient .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patient old equal 18 year 2 . The patient acceptable candidate treatment drugeluting stent accordance applicable guideline percutaneous coronary intervention , Instructions Use Resolute Integrity stent 3 . The patient legal representative inform nature trial consent participate authorize collection release his/her medical information signing Patient Informed Consent Form 4 . Intention implant least one Resolute Integrity stent percutaneous coronary intervention ( PCI ) 5 . Patient agree study procedure perform , willing comply protocolrequired evaluation 1 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , chromium , molybdenum , polymer coating ( e.g . BioLinx ) sensitivity contrast medium , adequately premedicated 2 . History allergic reaction significant sensitivity drug zotarolimus , rapamycin , tacrolimus , everolimus , analogue derivative 3 . A woman pregnant , plan pregnant lactate 4 . Currently participate another trial 5 . Situation prevent dual antiplatelet therapy maintain throughout perisurgical period 6 . Previous enrollment China Resolute Integrity Study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>